Elevance Health, Inc. $ELV Stake Increased by Rothschild Investment LLC

Rothschild Investment LLC raised its stake in Elevance Health, Inc. (NYSE:ELV – Free Report) by 162.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,761 shares of the company’s stock after acquiring an additional 2,329 shares during the quarter. Rothschild Investment LLC’s holdings in Elevance Health were worth $1,462,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Field & Main Bank lifted its holdings in Elevance Health by 1.3% in the second quarter. Field & Main Bank now owns 1,883 shares of the company’s stock valued at $728,000 after buying an additional 25 shares during the period. Simplicity Wealth LLC lifted its stake in Elevance Health by 1.3% in the third quarter. Simplicity Wealth LLC now owns 1,939 shares of the company’s stock valued at $754,000 after buying an additional 25 shares in the last quarter. Tranquilli Financial Advisor LLC boosted its stake in Elevance Health by 1.3% in the 2nd quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company’s stock worth $805,000 after purchasing an additional 26 shares during the period. Mather Group LLC. boosted its position in shares of Elevance Health by 3.5% during the third quarter. Mather Group LLC. now owns 766 shares of the company’s stock worth $298,000 after buying an additional 26 shares during the period. Finally, 55 North Private Wealth LLC grew its stake in shares of Elevance Health by 4.5% during the 3rd quarter. 55 North Private Wealth LLC now owns 598 shares of the company’s stock worth $233,000 after acquiring an additional 26 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Price Performance

Shares of ELV opened at $390.88 on Friday. The business has a 50-day moving average of $416.40 and a 200-day moving average of $376.69. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.47. The company has a market capitalization of $84.45 billion, a price-to-earnings ratio of 16.67, a price-to-earnings-growth ratio of 1.91 and a beta of 0.63. Elevance Health, Inc. has a 1 year low of $274.84 and a 1 year high of $450.69.

Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The firm had revenue of $50.44 billion during the quarter, compared to analyst estimates of $49.28 billion. During the same quarter last year, the business earned $6.03 EPS. The company’s revenue was up .7% compared to the same quarter last year. As a group, equities research analysts anticipate that Elevance Health, Inc. will post 29.16 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s payout ratio is 29.34%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ELV shares. UBS Group raised their price target on Elevance Health from $460.00 to $523.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Morgan Stanley boosted their price target on Elevance Health from $404.00 to $449.00 and gave the company an “equal weight” rating in a research note on Thursday, October 22nd. Guggenheim increased their target price on shares of Elevance Health from $460.00 to $485.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Argus upgraded Elevance Health from a “hold” rating to a “buy” rating and set a $510.00 price target on the stock in a research report on Wednesday. Finally, Wall Street Zen upgraded Elevance Health from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Sixteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $458.91.

Check Out Our Latest Stock Analysis on ELV

Insider Buying and Selling

In other news, EVP Ratnakar Lavu sold 1,300 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $440.00, for a total transaction of $572,000.00. Following the completion of the sale, the executive vice president directly owned 14,849 shares of the company’s stock, valued at $6,533,560. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Mark Kaye sold 10,584 shares of the firm’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the transaction, the chief financial officer owned 19,919 shares in the company, valued at approximately $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.34% of the stock is currently owned by corporate insiders.

Elevance Health Profile

(Free Report)

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Featured Articles

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.